Cooley LLP advised Engine Biosciences on the deal.
Engine Biosciences, a company deciphering complex biology to create medicines, announced its $43 million Series A financing round.
Polaris Partners led the round, which also included participation from Invus, 6 Dimensions Capital, WuXi AppTec, DHVC, EDBI, Baidu Ventures, Vectr Ventures, Goodman Capital, WI Harper and Nest.Bio. Engine Biosciences will use the new capital to expand its portfolio of precision oncology therapeutics, prepare for its first clinical programs and scale its proprietary technology platform.
Located in Singapore and Silicon Valley, Engine Biosciences operates at the intersection of data science, machine learning, high-throughput biology experimentation, combinatorial genetics, chemistry and drug discovery. Its technologies enable researchers and drug developers to uncover the gene interactions and biological networks underlying diseases faster and more cost-effectively than conventional methods.
The Cooley team led by Singapore-based partner Matthew Bartus (Picture). It also included James Jackson, Xinwei Li, Lila Hope, Jon Beh, Andrew Harline, Chris Kimball, Kevin King, Dillon Martinson, Mika Reiner Mayer, Rebecca Ross and Patrick Stewart.
Involved fees earner: Matthew Bartus – Cooley LLP; Andrew Harline – Cooley LLP; Lila Hope – Cooley LLP; James Jackson – Cooley LLP; Christopher Kimball – Cooley LLP; Kevin King – Cooley LLP; Xinwei Li – Cooley LLP; Dillon Martinson – Cooley LLP; Mika Reiner Mayer – Cooley LLP; Rebecca Ross – Cooley LLP; Patrick Stewart – Cooley LLP;
Law Firms: Cooley LLP;
Clients: Engine Biosciences;